Blog
RSS FeedPosted by Michael Wonder on 29 Apr 2021
CCRM and Amgen partner to advance emerging medical innovations
29 April 2021 - New fund to support regenerative medicine discoveries with high potential impact for patients. ...
Posted by Michael Wonder on 26 Apr 2021
Kite's Yescarta (axicabtagene ciloleucel) reimbursed in Alberta for the treatment of certain types of aggressive non-Hodgkin lymphoma
23 April 2021 - Gilead Canada announced today that Yescarta (axicabtagene ciloleucel) is now available in Alberta as a treatment ...
Posted by Michael Wonder on 10 Oct 2019
Novartis completes certification of initial sites in Quebec for first approved Canadian CAR-T therapy, Kymriah (tisagenlecleucel)
9 October 2019 - Quebec government to reimburse Kymriah therapy for certain patients with life-threatening cancers who are in critical ...
Posted by Michael Wonder on 16 Apr 2019
New genetic therapies in cancer treatment could impact benefits plans
12 April 2019 - In September 2018, Health Canada approved, for the first time, the use of a chimeric antigen ...
Posted by Michael Wonder on 21 Jan 2019
Will price be a barrier to new cancer immunotherapy?
19 January 2019 - Advisory group CADTH recommends no funding for new CAR-T therapy until drug company lowers cost. ...
Posted by Michael Wonder on 17 Jan 2019
Gene therapy drug Kymriah should be publicly covered if manufacturer drops price, report recommends
16 January 2019 - A groundbreaking gene therapy for cancer could cost the Canadian health care system more than $400 ...